HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pasi A Jänne Selected Research

Nivolumab

1/2018STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
10/2017Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.
4/2016Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
1/2016Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pasi A Jänne Research Topics

Disease

179Neoplasms (Cancer)
12/2023 - 12/2003
175Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2024 - 05/2002
90Lung Neoplasms (Lung Cancer)
12/2023 - 01/2003
27Disease Progression
12/2023 - 05/2004
22Adenocarcinoma of Lung
01/2023 - 06/2004
14Neoplasm Metastasis (Metastasis)
02/2024 - 09/2006
11Mesothelioma
01/2022 - 11/2004
11Malignant Mesothelioma
12/2016 - 09/2002
8Epilepsy (Aura)
01/2019 - 04/2016
6Carcinoma (Carcinomatosis)
12/2023 - 05/2004
6Breast Neoplasms (Breast Cancer)
11/2021 - 07/2006
5Colorectal Neoplasms (Colorectal Cancer)
04/2024 - 09/2011
5Diarrhea
06/2022 - 04/2009
4Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2023 - 12/2003
4Nausea
01/2021 - 05/2004
4Leukemia
01/2016 - 04/2009
3Brain Neoplasms (Brain Tumor)
12/2023 - 03/2005
3Bites and Stings (Sting)
11/2022 - 01/2022
3Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
10/2018 - 03/2010
3Neuroblastoma
10/2018 - 12/2010
3Circulating Neoplastic Cells
01/2018 - 03/2016
3Pneumonia (Pneumonitis)
04/2016 - 07/2006
3Fatigue
06/2013 - 04/2009
3Neutropenia
01/2013 - 07/2008
3Adenocarcinoma
06/2012 - 05/2004
3Carcinogenesis
10/2008 - 10/2005
2Pancreatic Neoplasms (Pancreatic Cancer)
12/2023 - 08/2007
2Stomatitis
06/2022 - 11/2014
2Stomach Neoplasms (Stomach Cancer)
01/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

108ErbB Receptors (EGF Receptor)IBA
12/2023 - 09/2002
77Tyrosine Kinase InhibitorsIBA
05/2024 - 05/2005
58Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2021 - 05/2005
43Gefitinib (Iressa)FDA Link
11/2019 - 05/2004
30Phosphotransferases (Kinase)IBA
12/2023 - 06/2004
24osimertinibIBA
12/2023 - 04/2015
20CrizotinibIBA
01/2021 - 10/2010
18DNA (Deoxyribonucleic Acid)IBA
01/2022 - 05/2004
18Anaplastic Lymphoma KinaseIBA
10/2018 - 07/2008
16Biomarkers (Surrogate Marker)IBA
12/2023 - 07/2006
15Immune Checkpoint InhibitorsIBA
01/2022 - 12/2015
13PlatinumIBA
12/2023 - 09/2007
13Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/2015 - 01/2003
12Proteins (Proteins, Gene)FDA Link
12/2023 - 04/2009
11Cisplatin (Platino)FDA LinkGeneric
11/2023 - 11/2004
10Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2022 - 05/2007
9adagrasibIBA
04/2024 - 01/2020
9Pemetrexed (MTA)FDA Link
12/2023 - 07/2005
9Monoclonal AntibodiesIBA
01/2023 - 07/2006
8Cetuximab (Erbitux)FDA Link
04/2024 - 08/2005
8Cell-Free Nucleic AcidsIBA
12/2023 - 03/2014
8LigandsIBA
10/2022 - 10/2005
7AfatinibIBA
12/2018 - 01/2016
6trastuzumab deruxtecanIBA
04/2024 - 01/2020
6Carboplatin (JM8)FDA LinkGeneric
11/2023 - 05/2003
6Adenosine Triphosphate (ATP)IBA
01/2021 - 12/2009
6dacomitinibIBA
01/2017 - 12/2007
6Docetaxel (Taxotere)FDA Link
01/2017 - 05/2002
5AZD 6244IBA
06/2022 - 03/2012
5GemcitabineFDA Link
01/2014 - 11/2004
4Immunoconjugates (Immunoconjugate)IBA
04/2024 - 01/2020
4NucleotidesIBA
11/2023 - 09/2012
4mobocertinibIBA
01/2023 - 01/2021
4tyrosine receptor (receptor, tyrosine)IBA
01/2022 - 10/2008
4Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2021 - 06/2004
4neratinibIBA
01/2020 - 06/2006
4NivolumabIBA
01/2018 - 01/2016
4TOR Serine-Threonine KinasesIBA
10/2014 - 08/2007
4Epidermal Growth Factor (EGF)IBA
04/2014 - 10/2005
3AntigensIBA
01/2023 - 01/2018
3RNA (Ribonucleic Acid)IBA
01/2023 - 01/2022
3human ERBB2 proteinIBA
01/2023 - 01/2021
3Mitogen-Activated Protein KinasesIBA
10/2021 - 05/2007
3Trastuzumab (Herceptin)FDA Link
01/2021 - 07/2006
3Bevacizumab (Avastin)FDA Link
10/2019 - 08/2008
3EverolimusFDA Link
01/2018 - 08/2007
3ParaffinIBA
12/2012 - 02/2006
3Formaldehyde (Formol)FDA Link
12/2012 - 02/2006
3Paclitaxel (Taxol)FDA LinkGeneric
06/2012 - 09/2010
3Insulin (Novolin)FDA Link
04/2012 - 09/2009
3Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
10/2010 - 11/2005
3AntibodiesIBA
03/2010 - 01/2003
2patritumab deruxtecanIBA
12/2023 - 01/2022
2Surface Antigens (Surface Antigen)IBA
01/2023 - 01/2018
21- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA
01/2023 - 12/2016
2Protein Kinases (Protein Kinase)IBA
01/2022 - 01/2021
2B7-H1 AntigenIBA
01/2022 - 08/2017
2amivantamab-vmjwIBA
01/2022 - 10/2021
2Messenger RNA (mRNA)IBA
09/2021 - 01/2016
2Drug CombinationsIBA
03/2021 - 01/2020
2Circulating Tumor DNAIBA
01/2021 - 03/2016
2Cysteine (L-Cysteine)FDA Link
01/2021 - 01/2020
2Alanine Transaminase (SGPT)IBA
01/2021 - 10/2012

Therapy/Procedure

112Therapeutics
12/2023 - 05/2004
41Drug Therapy (Chemotherapy)
12/2023 - 01/2003
9Radiotherapy
10/2019 - 05/2003
8Immunotherapy
01/2023 - 01/2016
6Adjuvant Chemotherapy
10/2019 - 11/2004
3Chemoradiotherapy
05/2024 - 05/2004
3Precision Medicine
01/2018 - 03/2012
3Aftercare (After-Treatment)
06/2014 - 07/2006